Fused Pyrimidine-Based Drug Discovery

Raj Kumar

2022年10月 · Elsevier

电子书

378

页

符合条件

评分和评价未经验证了解详情

关于此电子书

Fused Pyrimidine-Based Drug Discovery covers all categories of fused-pyrimidines along with pharmacological and in silico studies. It covers the chemistry and biological activities, as well as the design of novel fused-pyrimidine scaffolds. N-Heterocyclic scaffolds are found in most known drug candidates, and are of interest to medicinal and organic chemists to design, synthesize and evaluate their biological properties. A variety of fused-pyrimidine molecules have been synthesized and extracted from natural resources, and are found to exhibit various biological activities such as antifolates, anticancer agents, analgesics, antimetabolites, CNS active agents and many more. Some of these scaffolds like purines are also known to have involvement in biological processes and are part of the framework of genetic material. This book focuses on the classification, structural chemistry, and chemical and physical properties along with various approaches for their synthesis. This book is ideal for researchers in organic chemistry both in academic and industrial settings, postgraduates in chemistry and medicinal chemistry. - Covers US FDA approved fused pyrimidine containing drugs and their analyses - Comprises classification based upon fusion of carbocyclic/heterocyclic rings(s) with a pyrimidine ring, and features their synthetic schemes, approaches and strategies - Includes new fused-pyrimidine scaffolds, allowing the researcher to predict the mechanisms involved in their synthesis - Covers fused pyrimidine containing bioactive compounds from the natural sources - Covers in silico studies of known fused pyrimidines and Structure-Activity Relationship (SAR), which will encourage the development of new or modified existing scaffolds with specific biological activities

作者简介

Dr. Raj Kumar, FRSC, is currently working as Dean of School of Health Sciences, and a Professor at the Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India. He obtained his Ph.D. in Medicinal Chemistry (2007) from NIPER, Mohali, India and completed his postdoctoral fellowship (2007-2008) at the University of Maryland Baltimore County (UMBC), Maryland where he co-invented a fused heterocycle RK-33 (Raj Kumar-33) molecule for the treatment of Lung Cancer. Dr. Kumar has published more than 90 peer-reviewed research papers (h index = 33; Scopus) in leading Medicinal/Organic/Pharmaceutical Chemistry Journals with a cumulative impact factor > 300. Dr. Kumar has been featured in the list of top 2% international scientists “Updated Science-wide Database of Stanford Citation Indicators released by Stanford University, USA and published by Elsevier BV on 19th October 2021. His research interests focus on the design and synthesis of novel fused heterocycles of biological importance.